Cord blood (CB) is a useful source of hemopoietic stem cells (HSCs) for transplantation. However, its use is hampered by the limited number of available cells, which in turn can cause delayed engraftment. 1 Therefore, protocols for graft manipulation have been developed, with the aim of expanding the number of HSCs. In our previous studies, we described a static serum-free system for ex vivo expansion of purified CB CD34 þ cells, including thrombopoietin, Flt-3 ligand, interleukin (IL)-6 and IL-11, which was able to induce significant and sustained ex vivo expansion of primitive CB HSCs. 2 In order to evaluate the safety and therapeutic potential of expanded CB HSCs, we designed a clinical protocol based on transplantation of ex vivo expanded, highly purified CD34 þ cells into pediatric patients. The translation of bench-based techniques into clinical procedures did not merely consist of replacing research reagents and materials with clinicalgrade products, but also in selecting a suitable cell purification system. Specifically, we needed to adapt the use of a closed, clinical-grade automated device designed to process large-volume, fresh leukapheresis products (CliniMACS, Miltenyi Biotech, Gladbach, Germany), to the selection of CD34 þ cells from small-volume thawed CB samples. Moreover, the new procedure required validation on CB units cryopreserved either as whole blood (unfractionated) or after removal of a large proportion of red cells (volume reduction), which are the two processing methods in use in CB banking.
To this end, we processed 10 cryopreserved and thawed CB samples (five unfractionated and five volume reduced). Units were selected randomly from routine CB donations, which were close to, but did not reach the minimum volume (60 ml) or number of NC (800 Â 10 6 ) required for banking, or were discarded for clinical reasons. CB units were collected after maternal informed consent. Volume reduction was carried out with an automated blood component separation device (Compomat G-4, Fresenius, Schweinfurt, Germany; CB was aseptically transferred into a top-andbottom Compoflex bag (Fresenius), centrifuged at 2900 g for 12 min and a 39 ml buffy coat was collected. The median (and range) numbers of NC and CD34 þ cells before cryopreservation were 603 Â 10 6 (289-1270) and 2.5 Â 10 6 (1.5-6.9), respectively. Both the unfractionated and the volume-reduced CB units were cryopreserved with our standard procedure (10% final DMSO concentration), thawed according to Rubinstein et al, 3 labeled with CD34 monoclonal antibody conjugated to superparamagnetic particles (CD34 CliniMACS reagent, Miltenyi Biotech) and selected using the CliniMACS system, adjusting the manufacturer's instructions to the limited number of NC and CD34 þ cells contained in each sample. According to this adjustment, we maintained the concentration of NC before selection between 3 and 5 Â 10 6 /ml. Moreover, the immunoselection was performed using a new low-capacity tubing set with a small separation column (CliniMACS Tubing set 150). The analysis of the CD34 þ cell-enriched fraction was performed by flow cytometry with an anti-CD34 monoclonal antibody (hpca-2; Becton Dickinson, BD, San Jose, CA, USA). The percentage of CD34 þ cells was evaluated on the gate of the CD45 þ cells.
The contents of NC and CD34 þ cells before and after immunoselection are shown in Table 1 . After immunoselection, the median purity and recovery of CD34 þ cells were 79.5 and 31%, respectively.
Although several studies have been published on the selection of CD34 þ cells from thawed CB, few experiences exist regarding the translation of bench-based cell purification techniques to the clinical setting. McNiece et al 4 evaluated two clinical scale devices for CD34 þ cell selection from CB cryopreserved after gradient sedimentation, Isolex 300i (Baxter Healthcare) and CliniMACS. They obtained a median purity and recovery of 51 and 38% with the Isolex 300i and 54 and 80% with the CliniMACS instrument, respectively. Querol et al 5 optimized a method for CD34 þ cell selection from CB cryopreserved after HES sedimentation. They used the Isolex device and obtained a mean purity and yield of 69 and 52%, respectively. More recently, Eichler et al 6 obtained a median yield of 30.8% after CD34 þ cell immunoselection of thawed CB buffy coats. They showed a correlation between the removal of dead or damaged cells and the Table 1 Purity and yield of CD34+ cells (median and range), before and after immunoselection of thawed CB samples with the CliniMACS instrument 
